scholarly journals CLINICAL AND MOLECULAR ASPECTS OF MUCINOUS OVARIAN TUMORS: ETIOPATHOGENESIS, INDIVIDUALIZATION OF TREATMENT

2010 ◽  
Vol 1 (3) ◽  
pp. 21-31
Author(s):  
A G Kedrova ◽  
S A Levakov ◽  
O R Shablovskiy ◽  
N S Vanke ◽  
O V Nechaeva ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Abdominal Cavity ◽  
Ovarian Tumors ◽  
Normal Ovary ◽  
Expert Pathologist ◽  
In Series ◽  
Molecular Aspects ◽  
Mucinous Ovarian Tumors ◽  
Review Criteria

To determine the prognosis and prognostic factors in series of mucinous tumors of the ovary (MTO) we included 34 patients in our retrospective review. Criteria were defined: 1.centralized histological review by our expert pathologist; 2. high risk of peritoneal pseudomyxoma or any synchronous malignant tumor in the abdominal cavity; 3. available data on the management and outcomes of patients. We found specific markers overexpression in mucinous ovarian tumors compared to their normal ovary tissues and serous type ovarian tumors by analysis of serum CA 19,9, CEA and immunohistochemistry. These results suggest that mucinous tumors of the ovary have distinctive cancergenesis and may attribute to the progression of the mucinous ovarian cancer.

scholarly journals The forkhead box L2 transcription factor (FOXL2) is differentially expressed in high-grade serous ovarian cancers.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Ovarian Tumors ◽  
High Grade ◽  
Normal Ovary ◽  
Primary Tumors ◽  
Forkhead Box ◽  
Ovarian Cancers

Ovarian cancer is the most lethal gynecologic cancer (1). We sought to identify genes associated with high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with HGSC using published microarray data (2, 3). We identified the forkhead box L2, (FOXL2) (4) as among the genes whose expression was most different in HGSC ovarian tumors. FOXL2 expression was significantly lower in ovarian tumors relative to normal ovary. FOXL2 has established roles in ovarian development (4, 5), and the FOXL2 gene is mutated in granulosa-cell tumors of the ovary (6). These data indicate FOXL2 might also be perturbed, at the level of gene expression, in high-grade serous ovarian cancers.

scholarly journals PEG3 is differentially expressed in high-grade serous ovarian cancers.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Ovarian Tumors ◽  
Differentially Expressed ◽  
High Grade ◽  
Normal Ovary ◽  
Primary Tumors ◽  
Ovarian Cancers

Ovarian cancer is the most lethal gynecologic cancer (1-3). We sought to identify genes associated with high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with HGSC using published microarray data (4, 5). We identified paternally expressed gene 3 (PEG3) (6) as among the genes whose expression was most different in HGSC ovarian tumors. PEG3 expression was significantly lower in ovarian tumors relative to normal ovary. In one dataset, an anti-sense transcript produced at the PEG3 locus was among those most differentially expressed between HGSC tumors and benign ovarial tissue. These data indicate that significant changes in expression at the PEG3 imprinted locus could be a feature of high-grade serous ovarian cancers.

scholarly journals CASP12 is differentially expressed in high-grade serous ovarian cancers.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Global Gene Expression ◽  
Ovarian Tumors ◽  
High Grade ◽  
Normal Ovary ◽  
Primary Tumors ◽  
Ovarian Cancers

Ovarian cancer is the most lethal gynecologic cancer (1). To identify genes associated with high-grade serous ovarian cancer (HGSC), we used published microarray data (2, 3) to compare global gene expression profiles of the normal ovary with that of primary tumors from women diagnosed with HGSC. We identified caspase-12 (CASP12) (4) as among the genes whose expression was most quantitatively different in HGSC ovarian tumors. CASP12 expression was decreased in ovarian tumors when compared to normal ovary. These data indicate that CASP12 might be relevant to the biology of high-grade serous ovarian cancers.

scholarly journals Immune Cells in the Normal Ovary and Spontaneous Ovarian Tumors in the Laying Hen (Gallus domesticus) Model of Human Ovarian Cancer

PLoS ONE ◽  
2013 ◽  
Vol 8 (9) ◽  
pp. e74147 ◽  
Author(s):  
Michael J. Bradaric ◽  
Krishna Penumatsa ◽  
Animesh Barua ◽  
Seby L. Edassery ◽  
Yi Yu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune Cells ◽  
Laying Hen ◽  
Gallus Domesticus ◽  
Ovarian Tumors ◽  
Human Ovarian Cancer ◽  
Normal Ovary

scholarly journals BIRC5 is differentially expressed in epithelial ovarian cancer.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Progression ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Ovarian Tumors ◽  
Normal Ovary ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We sought to identify genes associated with epithelial ovarian cancer and the high-grade serous ovarian cancer (HGSC) subtype by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with epithelial cancer and HGSC in specific using published microarray data (2, 3). We identified the gene encoding the baculoviral inhibitor of apoptosis repeat (IAP) containing 5, BIRC5 as among the genes whose expression was most different in epithelial ovarian cancer and in HGSC ovarian tumors. BIRC5 expression was significantly higher in ovarian tumors relative to normal ovary. Correlation of BIRC5 expression with survival outcomes in patients with ovarian cancer was complex, with low expression favorable early in disease and high expression favorable later in disease. These data indicate that expression of BIRC5 is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. BIRC5 may be relevant to pathways underlying ovarian cancer progression.

scholarly journals STARD9 is differentially expressed in high-grade serous ovarian cancers.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Regulatory Protein ◽  
Ovarian Tumors ◽  
High Grade ◽  
Normal Ovary ◽  
Lipid Transfer ◽  
Primary Tumors ◽  
Ovarian Cancers

Ovarian cancer is the most lethal gynecologic cancer (1-3). We sought to identify genes associated with high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with HGSC using published microarray data (4, 5). We identified the steroidogenic acute regulatory protein-related lipid transfer (START) domain containing protein STARD9 (6) as among the genes whose expression was most different in HGSC ovarian tumors. STARD9 expression was significantly lower in ovarian tumors relative to normal ovary. These data reveal perturbed expression of a mitotic kinesin and the only kinesin located at the daughter centriole (6) in high-grade serous ovarian cancers.

scholarly journals Prepronociceptin is differentially expressed in epithelial ovarian cancer.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Progression ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Ovarian Tumors ◽  
High Grade ◽  
Normal Ovary ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We sought to identify genes associated with epithelial ovarian cancer and the high-grade serous ovarian cancer (HGSC) subtype by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with epithelial cancer and HGSC in specific using published microarray data (2, 3). We identified the gene encoding prepronociceptin, PNOC, as among the genes whose expression was most different in epithelial ovarian cancer and in HGSC ovarian tumors. PNOC expression was significantly higher in high-grade serous ovarian tumors relative to normal ovary. PNOC expression correlated with overall survival in patients with ovarian cancer. These data indicate that expression of PNOC is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. PNOC may be relevant to pathways underlying ovarian cancer progression.

scholarly journals CBX7 is differentially expressed in high-grade serous ovarian cancers.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Global Gene Expression ◽  
Ovarian Tumors ◽  
High Grade ◽  
Normal Ovary ◽  
Primary Tumors ◽  
Ovarian Cancers

Ovarian cancer is the most lethal gynecologic cancer (1-3). We sought to identify genes associated with high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with HGSC using published microarray data (4,5). We identified the chromobox homolog 7 (CBX7) (6) as among the genes whose expression was most different in HGSC ovarian tumors. CBX7 expression was significantly lower in ovarian tumors relative to normal ovary. These data reveal perturbed expression of a tumor suppressor (7) with epigenetic activity at lysine 27 of histone H3 (H3K27) (8) in high-grade serous ovarian cancers.

scholarly journals The CCHC-type zinc finger ZCCHC18 is differentially expressed in high-grade serous ovarian cancers.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Zinc Finger ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Significant Loss ◽  
Ovarian Tumors ◽  
High Grade ◽  
Normal Ovary ◽  
Primary Tumors ◽  
Ovarian Cancers

Ovarian cancer is the most lethal gynecologic cancer (1). We sought to identify genes associated with high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with HGSC using published microarray data (2, 3). We identified the zinc finger CCHC-type containing 18 (ZCCHC18) as among the genes whose expression was most different in HGSC ovarian tumors. ZCCHC18 expression was significantly lower in ovarian tumors relative to normal ovary. These data indicate that significant loss of ZCCHC18 expression could be a feature of high-grade serous ovarian cancers.

scholarly journals Diagnosis and treatment characteristics of mucinous ovarian tumors

2021 ◽  
Vol 70 (2) ◽  
Author(s):  
Tudor Rotaru ◽  
◽  
Rotaru Ludmila ◽  
Daniela Mocan ◽  
Nicu Balan ◽  
...  
Keyword(s):  
Tumor Marker ◽  
Abdominal Cavity ◽  
Clinical Signs ◽  
Laboratory Diagnosis ◽  
Ovarian Tumors ◽  
Diagnostic Methods ◽  
Diagnosis And Treatment ◽  
Ca 125 ◽  
Benign Ovarian Tumor ◽  
Mucinous Ovarian Tumors

Ovarian tumors occupy a special place in gynecological pathology due to their great diversity, diagnostic difficulties, specifying their evolutionary nature, establishing the prognosis and treatment. Ovarian mucinous tumors are a group of rare formations, with a cell of as yet undefined origin, but with an apparent progression from benign to borderline and carcinoma. The treatment of a benign ovarian tumor is surgical. Material and methods. The research in question was performed on a group of 50 patients, who were treated in the gynecology department of the IMSP Oncological Institute of the Republic of Moldova, with the diagnosis of mucinous ovarian tumors. Results. The study analyzed data on the diagnosis and treatment of mucinous ovarian tumors. The clinical diagnosis showed a unilateral ovarian involvement in 41 cases (82%) compared to the bilateral one registered in 9 patients (18%). All tumors were large and irregularly shaped. In the case of laboratory diagnosis in assessing the benign or malignant tumor potential, the tumor marker CA-125 was performed, in 41 patients the index was within the norm range from 0-35U / ml and only in 9 cases were there insignificant increases of 50-100U / ml. Ultrasonographic diagnosis is an important method in detecting mucinous ovarian tumors. The treatment of patients is surgical and, depending on the appearance of the tumor intraoperatively and age, they had a radical or less radical character. Conclusions. The most common clinical signs were fullness in the pelvis, dysuria, pain in the lumbar or sacral region. As usual, the mucous ovarian tumors are large. The CA-125 tumor marker was in most cases within the normal range. Imaging investigations are informative and some of them applied to all patients in the study. Endoscopic diagnostic methods are less informative in mucinous ovarian tumors due to bulky formations and the risk of effusion of the mucin into the abdominal cavity.

Sign in / Sign up

Export Citation Format

Share Document